Skip to main content
James Armitage, MD, Oncology, Omaha, NE

JamesOArmitageMD

Oncology Omaha, NE

Professor, Internal Medicine, University of Nebraska Medical Center College of Medicine

Dr. Armitage is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Armitage's full profile

Already have an account?

  • Office

    988102 Nebraska Medical Ctr
    Omaha, NE 68198
    Phone+1 402-559-9800
    Fax+1 402-559-4835

Education & Training

  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1976 - 1977
  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1975 - 1976
  • University of Nebraska Medical Center College of Medicine
    University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1973 - 1975
  • University of Nebraska College of Medicine
    University of Nebraska College of MedicineClass of 1973

Certifications & Licensure

  • NE State Medical License
    NE State Medical License 1973 - 2026
  • IA State Medical License
    IA State Medical License 1975 - 2000
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FASCO) American Society of Clinical Oncologists, 2007

Publications & Presentations

PubMed

Journal Articles

  • Do You Know TAFRO?  
    James O Armitage, Matthew A Lunning, Blood

Abstracts/Posters

  • The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma _ Single Institution Experience
    James O. Armitage, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML)
    James O. Armitage, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)
    James O. Armitage, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma
    Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin LymphomaNovember 14th, 2024
  • Immunotherapy Improves Survival in People with Advanced Hodgkin Lymphoma, Study Shows
    Immunotherapy Improves Survival in People with Advanced Hodgkin Lymphoma, Study ShowsOctober 16th, 2024
  • Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin’s Lymphoma
    Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin’s LymphomaOctober 16th, 2024
  • Join now to see all

Committees

  • Co-chair, 2015 Update Committee, American Society of Clinical Oncology (ASCO) 2015 - Present

Professional Memberships